Position in NVS
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$416,248
+$11,308 QoQ
Shares Held
2,656
+0.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#972
of 1,602 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Hilton Head Capital Partners, LLC holds $12,912,613 across 14 Drug Manufacturers - General names. NVS ranks #6 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,054 | $4,862,489 | |
| 2 | JNJ |
Johnson & Johnson
|
9,614 | $2,441,667 | |
| 3 | MRK |
Merck & Co., Inc.
|
15,656 | $2,011,796 | |
| 4 | AMGN |
Amgen Inc
|
3,927 | $1,422,045 | |
| 5 | ABBV |
AbbVie Inc.
|
2,889 | $726,987 | |
| 6 | NVS |
Novartis AG
This page
|
2,656 | $416,248 | |
| 7 | PFE |
Pfizer Inc
|
12,900 | $310,632 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
3,953 | $227,771 |
All Filings in NVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $416,248 | 2,656 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $404,940 | 2,651 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $363,287 | 2,635 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||